Product Program year 2025 Source: CMS Open Payments

Triluron

Device Osteoarthritis

Open in the dashboard

General payments

$118,430

5,714 payments

Research payments

$0

0 payments

Through program year 2025, $118,430 in general payments and $0 in research payments were reported against Triluron (Osteoarthritis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2025 General $22,221 1,045
2024 General $23,911 1,120
2023 General $26,395 1,229
2022 General $29,410 1,473
2021 General $16,493 847

Breakdown

Who paid General payments · program years 2021–2025
  1. Fidia Pharma USA Inc. $118,430 5,714 payments
Top recipients General payments · program year 2025
  1. Archie Adams Family Medicine · Covington, WA $219 <1% · 2 payments
  2. Daniel Oh Pain Medicine · Renton, WA $219 <1% · 2 payments
  3. Gregory Auzenne Pain Medicine · Meridian, MS $183 <1% · 1 payment
  4. Patrick Akin Interventional Pain Medicine · Turlock, CA $167 <1% · 1 payment
  5. Eric Anderson Sports Medicine · Spokane, WA $119 <1% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Orthopaedic Surgery $3,591 16% · 143 practitioners
  2. Physician Assistant $2,670 12% · 122 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $1,798 8% · 83 practitioners
  4. Pain Medicine Anesthesiology $1,576 7% · 45 practitioners
  5. Interventional Pain Medicine Pain Medicine $1,431 7% · 51 practitioners

The top 5 of 53 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $2,888 13% · 123 recipients
  2. New York $2,252 10% · 95 recipients
  3. California $2,231 10% · 82 recipients
  4. Florida $1,765 8% · 83 recipients
  5. Georgia $1,634 7% · 75 recipients

The top 5 of 38 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

5,714 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record